Examining the effects of national initiatives to improve the physical health of people with psychosis in England: secondary analysis of data from the National Clinical Audit of Psychosis

Ryan Williams, 1,2 © Sagana Natkulasingam, 2 Beatrice Tooke, 1 Ella Webster, 1 Alan Quirk, 1 Jo Smith, 1,4 Mike J. Crawford 1,2 ©

Aims and Methods To examine whether national initiatives have led to improvements in the physical health of people with psychosis. Secondary analysis of a national audit of services for people with psychosis. Proportions of patients in ‘good health’ according to seven measures, and one composite measure derived from national standards, were compared between multiple rounds of data collection.

Results The proportion of patients in overall ‘good health’ under the care of Early Intervention in Psychosis teams increased from 2014–2019, particularly for measures of smoking, alcohol and substance use. There was no overall change in the proportion of patients in overall ‘good health’ under the care of Community Mental Health Teams from 2011–2017. However, there were improvements in alcohol use, blood glucose and lipid levels.

Clinical implications There have been modest improvements in the health of people with psychosis over the last nine years. Continuing efforts are required to translate these improvements into reductions in premature mortality.

Keywords Physical health; psychosis; schizophrenia; community mental health teams; early intervention.

Concerns have repeatedly been raised regarding premature mortality among people with schizophrenia and other psychotic disorders. 1–6 People who experience psychosis die on average 10–20 years earlier than the general population. 7,8 Factors contributing to this inequality may include economic disadvantage, health risk behaviours and difficulties accessing and adhering to medical treatments. 9–11 These frequently translate to poor physical health, and psychotic disorders are strongly associated with unfavourable outcomes for a range of physical health measures: smoking status, weight, serum glucose levels, blood pressure and serum lipids.12,13 These issues can be compounded by metabolic side-effects of antipsychotic medication,14–17 and an increased risk of cardiovascular disease is widely accepted as the primary mediator of reduced life expectancy.4,18–20

National initiatives

In 2014, the National Institute for Health and Care Excellence (NICE) produced recommendations to guide screening and intervention for common physical health problems experienced by people with psychosis.21 The same year, NHS England announced a new Commissioning for Quality and Innovation (CQUIN) framework, providing financial incentives for physical health screening and interventions within secondary mental health services.22 The ‘Positive Cardiometabolic Health Resource’ was published, with support from the Royal Colleges of Psychiatrists, Physicians, Nursing and General Practice, establishing a user-friendly manual for clinicians providing care to patients with severe mental illness.23 Since these initiatives were implemented, there is some evidence that the quality of physical healthcare delivered to patients with psychosis has improved.24 However, there are ongoing concerns that this has not translated to an improvement in patients’ health. A recent study found that cardiometabolic risk factors were already pronounced in those presenting to services with a first episode of psychotic illness, and that physical health deteriorated during the first year of treatment.25 In light of these apparent contradictions, we aimed to investigate whether physical health has improved among people with psychotic disorders. We conducted a secondary analysis of data gathered over the past 9 years, during national audits of services for people with psychosis.
Method

All data for this study were collected during two audit rounds conducted as part of the National Clinical Audit of Psychosis (NCAP) by the Royal College of Psychiatrists. Both examined services providing care to people with psychotic disorders in England. A ‘core’ audit generated data on people under the care of community mental health teams (CMHTs), with three rounds of data collection in 2011, 2013 and 2017. A ‘spotlight’ audit collected additional data on the quality of care received by people with first-episode psychosis (FEP) who received care from early intervention for psychosis (EIP) teams. Three rounds of the spotlight audit were conducted in 2014, 2018 and 2019. All National Health Service (NHS) Provider Trusts in England with CMHTs and EIP teams that provided care to patients with psychotic disorders were invited to take part in these respective audits.

For both audits, all participating organisations were asked to provide an anonymised list of eligible patients who fulfilled inclusion criteria during a 12-month ‘sampling window’ before the point of data collection. From each list, 100 patients were randomly selected for inclusion in the audit. For the CMHT audit, patients were eligible for inclusion if they had an active period of care with a participating CMHT, were aged ≥18 years and had an established diagnosis of schizophrenia or schizoaffective disorder (ICD-10 codes F20/F25) recorded during the 12-month sampling period. Patients were excluded if they had received in-patient care or care from an EIP team during this period. For the EIP audit, patients were eligible for inclusion if they had an active period of care with a participating EIP team, were aged ≥14 years and had a diagnosed ‘first episode’ of any psychotic disorder (ICD-10 codes F20-F29) recorded during the 12-month sampling period. For the purposes of this study, we excluded any patients whose host organisation did not participate in all three rounds of the respective audit.

For both audits, staff from each organisation were asked to conduct a retrospective review of case notes from the sampling window, and extract data to complete an online data collection tool. The tool included questions on physical health measures, quantifying patients’ smoking status, alcohol use, blood pressure, body mass index (BMI), serum glucose, serum lipids and whether they were known to use illicit substances. The data collection tools for both audits were based on NICE guidance for management of psychotic disorders. They were developed in collaboration with patients and providers of psychiatric services, and carer representatives with lived experience of supporting patients with psychotic disorders. The tool was piloted by six volunteer trusts before the main audit, to ensure that the process was understandable and acceptable.

During the development of this project, the National Research Ethics Service and the Ethics and Confidentiality Committee of the National Information Governance Board advised that formal ethical approval and individual participants’ informed consent were not required because this was a secondary analysis of audit data and patient-identifiable data were not being collected. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

Exposure, outcome measures and covariates

The primary outcome measures for this study were whether patients were considered to be in ‘good health’, according to for seven discrete physical health measures and one composite measure. The seven measures of good health were smoking status (not currently smoking, e.g. non-smoker or ex-smoker), alcohol use (no recorded ‘harmful or hazardous’ alcohol use), illicit substance use (no recorded illicit substance use), blood pressure (normotensive, i.e. <140/90 mmHg), BMI (within normal range, i.e. 18.5–24.9), serum glucose (within normal range, i.e. fasting blood glucose <5.5 mmol/L and/or random plasma glucose <11.1 mmol/L and/or hemoglobin A1C <42 mmol/mol) and serum lipids (within normal range, i.e. total serum cholesterol <5.1 mmol/L and/or high-density lipoprotein >1 mmol/L and/or non-high-density lipoprotein <4.1 mmol/L). The definition of good health for each measure was based on the standards implemented by the national Mental Health Commissioning for Quality and Innovation analysis. To be considered in good health for the composite measure, patients had to fulfil the criteria for good health for all of the seven discrete measures.

In addition, patients’ age and gender were recorded, to provide demographic information about the overall sample for each audit.

Statistical methods

We used SPSS (version 26 for Windows) to analyse the study data. For each round of the audits, the proportion of patients with good health were calculated for each of the physical health measures and the composite measure. The variation in these proportions between each round of the two audits was then examined with binomial logistic regression.

Variation in demographic characteristics (age and gender) were compared between the CMHT and EIP audits, using t- and χ²-tests, respectively.

For many patients, data were not recorded for some of the physical health measures (presumably because it was not available in the clinical records, possibly because of patients refusing to undergo investigation or provide information). Missing values were not included in the analysis.

Results

For the CMHT audit, 57 NHS Provider Trusts submitted data for all three rounds. Data from 16,752 sets of case notes were analysed (4618 from the first round in 2011, 4785 from the second round in 2013 and 7349 from the third round in 2017). For the EIP audit, 54 NHS Provider Trusts submitted data for all three rounds. Data from 20,611 sets of case notes were analysed (2158 from the first round in 2014, 8768 from the second round in 2018 and 9685 from the third round in 2019).
Table 1 summarises the demographic characteristics (age and gender) for the total samples of the CMHT audit and EIP audit, respectively. Across the three rounds, patients in the CMHT audit were significantly older than those in the EIP audit, with mean ages of 47.11 years and 29.66 years, respectively \( (t(37361) = 156.94, P < 0.001) \). In the CMHT audit, 65.6% of the total sample were men, compared with 64.2% in the EIP audit, which was not a statistically significant difference.

Table 2 summarises the proportion of CMHT patients in good health according to each of our outcome measures (including the composite measure), and the variation in these proportions over time across the three rounds of the CMHT audit. There were variable amounts of missing data for each of the seven outcome measures, meaning that the composite measure could only be used for 31.3% (5243/16752) of CMHT patients.

There was some evidence of improvement in health. CMHT patients in the third round were significantly more likely than those in the first round to be in good health according to measures of alcohol use (odds ratio 1.48, 95% CI 1.31–1.67, \( P < 0.001 \)), blood glucose levels (odds ratio 2.12, 95% CI 1.89–2.36, \( P < 0.001 \)) and blood lipids (odds ratio 1.78, 95% CI 1.60–1.98, \( P < 0.001 \)). However, CMHT patients in the third round were less likely to be in good health for the illicit substance use measure (odds ratio 0.76, 95% CI 0.68–0.85, \( P < 0.001 \)), i.e. a higher proportion of CMHT patients were using illicit substances in 2017 compared with 2011. The proportion of CMHT patients in overall good health according to the composite measure was consistently low across all three rounds of the audit, and decreased from 3.3% in 2011 to 2.7% in 2017, although this was not statistically significant.

Table 3 summarises the proportion of EIP patients in good health according to each of our outcome measures (and the composite measure), and the variation in these proportions over time across the three rounds of the EIP audit. Similarly, there were variable amounts of missing data for each of the seven outcome measures, meaning that the composite measure could only be used for 56.4% (II 625/20 611) of EIP patients.

This audit also showed improvements in some of the measures of health over time: notably, those relating to smoking (odds ratio 1.22, 95% CI 1.11–1.35, \( P < 0.001 \)), alcohol use (odds ratio 1.43, 95% CI 1.23–1.68, \( P < 0.001 \)) and illicit substance use (odds ratio 1.86, 95% CI 1.68–2.07, \( P < 0.001 \)). Furthermore, the proportion of EIP patients with overall good health was significantly higher in the third round compared with the first (odds ratio 4.65, 95% CI 3.32–6.52, \( P < 0.001 \)), although this remained the minority (10.3%). Also, EIP patients in 2019 were significantly less likely than those in 2014 to be in good health for the BMI measure (odds ratio 0.69, 95% CI 0.60–0.79, \( P < 0.001 \)).

### Discussion

This study corroborates previous findings that the physical health of people with psychosis remains poor, despite an improvement in physical health screening and intervention following national initiatives implemented in England since 2014.24

Both CMHT and EIP audits showed improvements in health according to some of these measures, and deteriorations in others. The proportion of patients in overall good health according to a composite measure was low across all rounds of both audits, but did improve significantly post-2014 for those patients receiving care from EIP services.

Unhealthy weight remains a particular area of concern, with large proportions of patients in poor health according to BMI across all rounds of both audits, and a significant deterioration over time in the EIP audit. This supports existing evidence that weight management is challenging for patients with psychotic disorders.29,30

We did find some evidence of a modest improvement in rates of smoking amongst patients under the care of EIP services post-2014. This contradicts recent studies where results have been more pessimistic,25,31 but would be in line with previous research suggesting a change in the epidemiology of smoking, with a gradual reduction in smoking in younger age groups.32 This improvement over time was not reflected in the CMHT audit, where patients were on average significantly older.

There was also a marked reduction post-2014 in the proportion of patients under the care of EIP services who were using illicit substances. This contrasted with the CMHT audit where the proportion increased slightly over time.

### Strengths and limitations

Data were obtained from large, heterogeneous samples over a 9-year period: all NHS Trusts in England with CMHT and EIP services that provided care to patients with psychotic disorders were invited to participate in the respective audits. These data therefore represent a variety of different settings, and we would expect that results would be generalisable to similar patient groups across the country. The primary outcome measures we used to assess physical health are universally recognised as clinically important, and the thresholds for good health were based on national standards that have been widely used elsewhere.33–35

However, this study does have important limitations. First, this is an observational study and we do not know what caused the changes we observed. Although they may

### Table 1

|                      | CMHT audit | EIP audit |
|----------------------|------------|-----------|
| Age, mean (s.d.)     | 47.11 (+12.02) | 29.66 (+9.47) |
| Difference in age between audits was statistically significant as determined by t-test: \( t(37361) = 156.94, P < 0.001 \) |
| Gender, n (%)        |            |           |
| Male                 | 10,989 (65.6) | 13,232 (64.2) |
| Female               | 5763 (34.4)  | 7379 (35.8)  |
| Difference in gender between audits was not statistically significant as determined by \( \chi^2 \)-test: \( \chi^2 = 1.23, P = 0.267 \) |

CMHT, community mental health team; EIP, early intervention in psychosis.
reflect changes in services during this period, other changes in society are affecting population health, and these could be responsible for some or all the differences we detected.

The EIP and CMHT audits were conducted at different times, both before and after the CQUIN framework was implemented, and used different selection criteria. Differences in the physical health of patients between the two are therefore likely to reflect the differing clinical and socioeconomic demographic characteristics of the patients in each audit, as well as different processes of care. We were able to examine changes in physical health over time within each audit, by comparing different rounds. However, as each service provided a random sample of eligible patients at each round, subsequent rounds of the same audit did not necessarily include the same cohort, and so we are unable to make inferences about changes in health at the level of individual patients even within the same audit.

For both the EIP and CMHT audits, we were able to examine physical health measures before and after the introduction of the Commissioning for Quality and Innovation programme. Although the introduction of the programme was associated with a marked increase in the proportion of patients who were offered interventions for their physical health, we found only limited evidence that this resulted in changes to the health of people under the care of CMHTs.

These data were produced from retrospective case note audits at each round, and are therefore dependant on accurate reporting and documentation of events at the time of occurrence. Clinicians working in CMHTs and EIP services may not have had full access to records held by primary care, where some physical health screening may have occurred.

Also, there were variable amounts of missing data for each primary outcome measure, meaning that the composite measure could only be used for a relatively small proportion of the overall sample. However, the proportion of missing data did generally improve over subsequent rounds of each audit, possibly reflecting the previously noted incentivised improvements in screening rates and recording.

### Implications

We found some evidence that overall health improved for patients with psychotic disorders under the care of EIP services between 2014 and 2019. However, we did not find

| Table 2 | Proportion of people with psychosis with good health outcomes at each round of the community mental health team audit |
|---------|---------------------------------------------------------------------------------------------------------------|
|         | 2011 Audit | 2013 Audit | 2017 Audit |
| Smoking | 1694/4016  | 1769/4286  | 2784/6342  |
| Alcohol use | 2691/3197  | 2887/3387  | 5686/6410  |
| Illicit substance use | 3377/3888  | 3699/4243  | 5281/6332  |
| Body mass index | 502/1202  | 571/2587  | 992/4537  |
| Blood pressure | 1900/2593  | 2191/2946  | 3642/4855  |
| Blood glucose levels | 1449/2297  | 1502/2690  | 3393/4332  |
| Blood lipids | 924/2186  | 1143/3002  | 2350/4152  |
| Composite measure | 33/1004  | 34/1372  | 76/2867  |

### Table 2

| Measure                      | 2011 Audit | 2013 Audit | 2017 Audit |
|------------------------------|------------|------------|------------|
| Smoking                      | 1694/4016  | 1769/4286  | 2784/6342  |
| Alcohol use                  | 2691/3197  | 2887/3387  | 5686/6410  |
| Illicit substance use        | 3377/3888  | 3699/4243  | 5281/6332  |
| Body mass index              | 502/1202  | 571/2587  | 992/4537  |
| Blood pressure               | 1900/2593  | 2191/2946  | 3642/4855  |
| Blood glucose levels         | 1449/2297  | 1502/2690  | 3393/4332  |
| Blood lipids                 | 924/2186  | 1143/3002  | 2350/4152  |
| Composite measure            | 33/1004  | 34/1372  | 76/2867  |
evidence of a similar improvement for patients under the care of CMHTs between 2011 and 2017. This may reflect differences in the model of care implemented by EIP services. Typically, these services advocate a more ‘intensive’ programme of intervention, with a focus on relatively smaller case-loads, proactive engagement and an increased frequency of contact.\textsuperscript{35–39} Although this approach is primarily intended to address psychiatric symptoms, multiple sources have suggested additional benefits for patients’ overall health, including increased levels of screening for physical health problems.\textsuperscript{40} EIP services may, therefore, have been better placed to implement changes resulting from the national initiatives rolled out in 2014.

However, the difference may also be because of differences in demographic and clinical characteristics between patients in the CMHT audit and the EIP audit. Patients in the EIP audit were younger on average, and were also likely to have had a shorter duration of psychiatric symptoms (as this audit specifically examined patients with a diagnosed ‘first episode’ of a psychotic disorder). These patients may have been more accepting of interventions intended to improve their physical health and, therefore, have seen greater improvements – even if CMHTs and EIP services had implemented identical changes since 2014. It may even be the case that people in younger age groups have become more ‘health conscious’ in recent years regardless of any intervention, as suggested by some epidemiological studies.\textsuperscript{32} However, this seems unlikely in these cohorts in light of previous findings that patients on EIP case-loads already had pronounced cardiovascular risk factors, even at the point of first presentation.\textsuperscript{25}

Both audits identified some isolated areas of improvement in specific measures. Interestingly, these differed between the patients in the CMHT audit, where there were improvements related to alcohol use, serum glucose level and lipids, and the EIP audit, where there were improvements in alcohol use, smoking and illicit substance use. Again, these changes may relate to demographic differences in the patients under the care of these respective services. Older patients may be more receptive to those that they perceive as reducing their risk of major cardiovascular events, such as reduction in serum glucose and lipids.

However, these varying improvements may also be because of differences in the treatment approaches adopted

| Table 3 | Proportion of people with psychosis with good health outcomes at each round of the audit of early intervention in psychosis services |
|---------|-------------------------------------------------|
|         | 2014 Audit | 2018 Audit | 2019 Audit |
|         | n/N | n/N | n/N |
| % | % | % |
| Odds ratio (95% CI), P-value | Odds ratio (95% CI), P-value | Odds ratio (95% CI), P-value |
| Smoking | 885/1808 | 4015/7832 | 4581/8487 |
|         | 49.0 | 51.3 | 54.0 |
| Reference | 1.10 (0.99–1.22), 0.080 | 1.22 (1.11–1.35), <0.001 |
| Alcohol use | 1620/1853 | 7021/7774 | 7749/8526 |
|         | 87.4 | 90.3 | 90.9 |
| Reference | 1.34 (1.15–1.57), <0.001 | 1.43 (1.23–1.68), <0.001 |
| Illicit substance use | 1182/1905 | 5711/7831 | 6410/8517 |
|         | 62.1 | 72.9 | 75.3 |
| Reference | 1.65 (1.48–1.83), <0.001 | 1.86 (1.68–2.07), <0.001 |
| Body mass index | 460/1044 | 2314/6667 | 2662/7566 |
|         | 44.1 | 34.7 | 35.2 |
| Reference | 0.68 (0.59–0.77), <0.001 | 0.69 (0.60–0.79), <0.001 |
| Blood pressure | 924/1106 | 5513/6733 | 6314/7750 |
|         | 83.5 | 81.9 | 81.5 |
| Reference | 0.89 (0.75–1.06), 0.195 | 0.87 (0.73–1.03), 0.104 |
| Blood glucose levels | 721/803 | 5071/5525 | 6175/6733 |
|         | 89.8 | 91.8 | 91.7 |
| Reference | 1.27 (0.99–1.63), 0.068 | 1.26 (0.99–1.61), 0.075 |
| Blood lipids | 506/741 | 3546/5416 | 4265/6564 |
|         | 68.3 | 65.5 | 65.0 |
| Reference | 0.88 (0.75–1.04), 0.141 | 0.86 (0.73–1.01), 0.079 |
| Composite measure | 37/1543 | 422/4465 | 576/5617 |
|         | 2.4 | 9.5 | 10.3 |
| Reference | 4.25 (3.02–5.98), <0.001 | 4.65 (3.32–6.52), <0.001 |
by CMHTs and EIP services. These findings merit further research to identify the factors explaining these variations, as well as the improvement in overall good health seen among those treated by EIP services. There may be elements where each service outperforms the other; for example, access to staff with training in physical health interventions, or improved links with primary care. Cohort or case–control studies could be used within CMHTs and EIP services to examine what interventions are associated with favourable physical health outcomes at an individual patient level. Qualitative studies to explore the perspectives of patients with psychosis may also identify effective strategies for improving patients’ physical health. It may also be of interest to include other services, such as assertive outreach teams, in future studies.

The fact that the EIP audit showed an improvement in rates of illicit substance use over time, but the CMHT audit showed the opposite, is an intriguing finding and of unclear significance. It does not seem to reflect the current understanding of the changing epidemiology of illicit substance use, and suggests that EIP services have been able to implement effective measures to support people in abstaining from illicit substances.

Interestingly, the one measure where both CMHTs and EIP services improved over time was alcohol use. Many drug and alcohol services in the UK are now provided by third-sector organisations rather than NHS mental health teams. The fact that both CMHTs and EIP services were able to effect improvement suggests that effective liaison with external organisations may be a key strategy for improvement, rather than attempting to deliver more services with internal infrastructure, which may already be overstretched.

Both audits showed specific areas where standards of physical health worsened over time. The findings related to patients’ weight are particularly concerning: the proportion of patients with a healthy BMI fell significantly across the three rounds of the EIP audit, and was universally low in the CMHT audit. Weight gain is a well-recognised and particular troubling side-effect of many antipsychotic medications. Given the implications of obesity for subjective well-being, medication adherence and therapeutic outcomes in the context of treatment for psychosis, and associated diabetes and cardiovascular risk and likelihood of premature mortality, improving interventions in this area needs to remain a focus for researchers. To date, studies of current weight management programmes for people with psychosis have produced mixed results.

In addition to these findings, it is also important to note that the majority of patients did not have adequate information recorded for all seven of the physical health measures recommended by nationally agreed standards. Only around half of patients in the EIP audit, and a third of those in the CMHT audit, had usable data recorded for all seven measures. The reasons for this are unclear from this project, and may reflect barriers to physical health screening, such as refusal, lack of provision or inadequate documentation. Clearly, accurate monitoring is required, and will be the focus of quality improvement activities before future rounds of the national audits.

In conclusion, we found limited evidence that overall health improved for patients with psychotic disorders under the care of CMHTs, following the enactment of national initiatives in 2014, although there was some evidence of improvement in specific areas. There was more substantial evidence of improvements for those patients under the care of EIP services. This may be a result of differences in CMHT and EIP services’ abilities to implement effective changes in policy and procedures, or demographic and clinical differences in their respective patients. However, these findings merit further research into the processes underlying the improvements in health, to improve the standard of care for people with psychosis.

About the authors
Ryan Williams is an NIHR Academic Clinical Fellow at the Department of Brain Sciences, Imperial College London, UK, and a Clinical Fellow with the College Centre for Quality Improvement, Royal College of Psychiatrists, UK. Sagana Nathkulasingam is a medical student at the Faculty of Medicine, Imperial College London, UK. Beatrice Tooke is an NCAP Programme Manager with the College Centre for Quality Improvement, Royal College of Psychiatrists, UK. Ella Webster is an NCAP Programme Manager with the College Centre for Quality Improvement, Royal College of Psychiatrists, UK. Alan Quirk is Head of Clinical Audit and Research for the College Centre for Quality Improvement, Royal College of Psychiatrists, UK. Veenu Gupta is a Service User Advisor with the College Centre for Quality Improvement, Royal College of Psychiatrists, UK. Paul French is an Honorary Professor with the Department of Psychological Sciences, University of Liverpool, UK, and an NCAP EIP Clinical Advisor with the College Centre for Quality Improvement, Royal College of Psychiatrists, UK. Mike J. Crawford is Professor of Psychiatry at the Department of Brain Sciences, Imperial College London, UK, and Director of the College Centre for Quality Improvement, Royal College of Psychiatrists, UK.

Data availability
All authors had access to the full study data-set. The data-set is held by the NCAP team at the College Centre for Quality Improvement, Royal College of Psychiatrists, and could be made available on request.

Acknowledgements
The authors would like to thank all members of the NCAP team at the Royal College of Psychiatrists, for their support with this study.

Author contributions
M.J.C. formulated the presented research question, designed the study and supervised the work. R.W. and S.N. performed the statistical analysis. R.W. drafted the manuscript and designed the figures. B.T., E.W., A.Q., V.G., P.F. and J.S. were involved in gathering and processing the NCAP data, and commented on drafts of the manuscript.

Funding
R.W. is supported by a UK National Institute for Health Research (NIHR) Academic Clinical Fellowship (ACF-2017-21-006). The NCAP is commissioned by the Healthcare Quality Improvement Partnership (HQIP) as part of the National Clinical Audit and Patient Outcome Programme (NCAPOP), which is funded by NHS England and the Welsh Government. The views expressed are those of the authors and not necessarily those of
the NHS, the NIHR, the Royal College of Psychiatrists or the Department of Health. The funders had no role in the design or conduct of the study; collection, management, analysis or interpretation of the data; preparation, review or approval of the manuscript; or decision to submit the manuscript for publication.

Declaration of interest

None.

References

1. Thomrock G, Rose D, Kassam A. Discrimination in health care against people with mental illness. Int Rev Psychiatry 2007; 19: 113–22.
2. Thomrock G. Physical health disparities and mental illness: the scandal of premature mortality. Br J Psychiatry 2011; 199: 441–2.
3. Hayes JJ, Miles J, Walters K, King M, Osborn D. A systematic review and meta-analysis of premature mortality in bipolar affective disorder. Acta Psychiatr Scand 2015; 131: 417–25.
4. Olsson M, Gerhard T, Huang C, Crystal S, Stroup TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 2015; 72: 1172–81.
5. Laursen TM, Nordenfelt M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol 2014; 10: 425–48.
6. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications a systematic review and meta-analysis. JAMA Psychiatry 2015; 72: 334–41.
7. Simon GE, Stewart C, Yarborough BJ, Lynch F, Coleman KJ, Beck A, et al. Mortality rates after the first diagnosis of psychotic disorder in adolescents and young adults. JAMA Psychiatry 2018; 75: 254–60.
8. Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry 2014; 13: 153–60.
9. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007; 116: 317–33.
10. McClellan JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19–32.
11. Vinogradova Y, Coupland C, Hippsley-Cox J, Whyte S, Penny C. Effects of severe mental illness on survival of people with diabetes. Br J Psychiatry 2010; 197: 272–7.
12. Brown S, Britwistle J, Roe L, Thompson G. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1995; 29: 697–701.
13. Osborn D, Nazareth I, King MB. Physical activity, dietary habits and coronary heart disease risk factor knowledge amongst people with severe mental illness. Soc Psychiatry Psychiatr Epidemiol 2007; 42: 787–93.
14. Howell S, Yarowoda E, Khwanda A, Rosen SD. Cardiovascular effects of psychotic illnesses and antipsychotic therapy. Heart 2010; 105: 1825–9.
15. Tschorner A, Engl J, Laimer M, Kaser S, Rettenbacher M, Fleischhacker WW, et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract 2007; 61: 1356–70.
16. Henderson DC, Vincenzi B, Andrea NV, Ulloa M, Copeland PM. Pathophysiologcal mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry 2015; 2: 452–64.
17. Sharpe JK, Hills AP. Atypical antipsychotic weight gain: a major clinical challenge. Aust New Zeal J Psychiatry 2003; 37: 705–9.
18. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64: 1123–31.
19. Bressee LC, Majumdar SR, Patton SB, Johnson JA. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res 2010; 117: 75–82.
20. Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s General Practice Research Database. Arch Gen Psychiatry 2007; 64: 242–9.
21. National Institute for Health and Care Excellence (NICE). Psychosis and Schizophrenia in Adults: Prevention and Management (Clinical Guidance CG178). NICE, 2014 (https://www.nice.org.uk/guidance/cg178).
22. NHS England. Commissioning for Quality and Innovation (CQUIN): 2014/15 Guidance. NHS England, 2014 (https://www.england.nhs.uk/wp-content/uploads/2014/12/sc-cquin-guid.pdf).
23. NHS England. Lester UK Adaptation: Positive Cardiometabolic Health Resource. NHS England, 2014 (https://www.rcpsych.ac.uk/docs/default-source/improving-care/cqcp/national-clinical-audits/rcplibrary/rcp7056-lester-uk-adaptation-4pp-a4-leaflet_4_updated.pdf?sfvrsn=7bc177e9_2).
24. Crawford MJ, Huddart D, Craig E, Zalewska K, Quirk A, Shiers D, et al. Impact of secondary care financial incentives on the quality of physical healthcare for people with psychosis: a longitudinal controlled study. Br J Psychiatry 2019; 215: 720–5.
25. Gaughan F, Stahl D, Stringer D, Hopkins D, Atakan Z, Greenwood K, et al. Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort study. Br J Psychiatry 2019; 215: 712–9.
26. Royal College of Psychiatrists. National Clinical Audit of Psychosis (NCAP). Royal College of Psychiatrists, 2019 (https://www.rcpsych.ac.uk/improving-care/cqcp/national-clinical-audits/national-clinical-audit-of-psychosis/).
27. IBM Corp. IBM SPSS Statistics for Windows, Version 26. IBM, 2019 (https://www.ibm.com/support/pages/download-ibm-spss-statistics).
28. Smith J, Griffiths LA, Band M, Hird-Smith R, Williams B, Bold J, et al. Early intervention in psychosis: effectiveness and implementation of a combined exercise and health behavior intervention within routine care. Front Endocrinol 2020; 11: 577691.
29. Bushe C, Haddad P, Peveler R, Pendlebury J. The role of lifestyle interventions and weight management in schizophrenia. J Psychopharmacol 2005; 19: 28–35.
30. Klingman EA, Viverito KM, Medoff DR, Hoffmann RM, Goldberg RW. Strategies, barriers, and motivation for weight loss among veterans living with schizophrenia. Psychiatr Rehabil J 2014; 37: 270–6.
31. Lally J, Spaducci G, Gardner-Sood P, Atakan Z, Greenwood K, Di Forti M, et al. Tobacco smoking and nicotine dependence in first episode and established psychosis. Asian J Psychiatry 2019; 43: 125–31.
32. Simpson CR, Hippsley-Cox J, Sheikh A. Trends in the epidemiology of smoking recorded in UK general practice. Br J Gen Pract 2010; 60: 187–92.
33. National Institute for Health and Care Excellence (NICE). Cardiometabolic Disease Prevention (Public Health Guidance PH25). NICE, 2010 (https://www.nice.org.uk/guidance/PH25/).
34. National Institute for Health and Care Excellence (NICE). Cardiovascular Risk Assessment and Lipid Modification (Quality Standard QS100). NICE, 2015 (https://www.nice.org.uk/guidance/qs100).
35. Department of Health. The Mental Health Policy Implementation Guide. Department of Health, 2001 (http://www.wales.nhs.uk/sites3/documents/776/CRIHT%20PIG.pdf).
36. NHS Digital. Health Survey for England 2018 [NS]. NHS Digital, 2019 (https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england/2018).
37. Brewer WJ, Lambert TJ, Witt K, Dileo J, Duff C, Crlenjak C, et al. Intensive case management for high-risk patients with first-episode psychosis: service model and outcomes. Lancet Psychiatry 2015; 2: 29–37.
38. Craig TK, Garety P, Power P, Rahman N, Colbert S, Fonells-Amorbo E, et al. The Lambeth Early Onset (LEO) Team: randomised controlled trial
of the effectiveness of specialised care for early psychosis. BMJ 2004; 329: 1067-70.

39 Singh K, Ghazi F, White R, Sarfo-Adu B, Carter P. Improving access to early intervention in psychosis (EIP): the 2-week wait for cancer comes to psychosis. BMJ Open Qual 2018; 7: e000190.

40 Mouko J, Sullivan R. Systems for physical health care for mental health patients in the community: different approaches to improve patient care and safety in an early intervention in psychosis service. BMJ Qual Improv Rep 2017; 6: u209141.w3798.

41 Degenhardt L, Bharat C, Glantz MD, Sampson NA, Scott K, Lim CCW, et al. The epidemiology of drug use disorders cross-nationally: findings from the WHO’s World Mental Health Surveys. Int J Drug Policy 2019; 71: 103-12.

42 Mohammadi D. Addiction services in England: in need of an intervention. Lancet Psychiatry 2014; 1: 421-2.

43 Drummond C. Cuts to addiction services are a false economy. BMJ 2017; 357: j2704.

44 Karamatskos E, Mulert C, Lambert M, Naber D. Subjective well-being of patients with schizophrenia as a target of drug treatment. Curr Pharm Biotechnol 2012; 13: 1490-9.

45 Chee GL, Wynaden D, Heslop K. The physical health of young people experiencing first-episode psychosis: mental health consumers’ experiences. Int J Ment Health Nurs 2019; 28: 330-8.

46 Every-Palmer S, Romans SE, Stubbs R, Tomlinson A, Gandhi S, Huthwaite M. Experiences of weight-loss surgery in people with serious mental illness: a qualitative study. Front Psychiatry 2020; 11: 419.

47 Holt RI, Hind D, Gossage-Worrall R, Bradburn MJ, Saxon D, McCrone P, et al. Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT. Health Technol Assess 2018; 22: 1-160.

48 Teasdale SB, Curtis J, Ward PB, Watkins A, Lederman O, Rosenbaum S, et al. The effectiveness of the Keeping the Body in Mind Xtend pilot lifestyle program on dietary intake in first-episode psychosis: two-year outcomes. Obes Res Clin Pract 2019; 13: 214-6.

49 Bredin SSD, Warburton DER, Lang DJ. The health benefits and challenges of exercise training in persons living with schizophrenia: a pilot study. Brain Sci 2013; 3: 821-48.